What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma.

Mooradian, Meghan J; Sullivan, Ryan J

Mooradian, Meghan J; Sullivan, Ryan J.

Oncology (Williston Park) ; 33(4): 141-8, 2019 Apr 15.

Article in En | MEDLINE | ID: mdl-30990567

Subject(s)

Antineoplastic Agents, Immunological/therapeutic use; CTLA-4 Antigen/antagonists & inhibitors; Melanoma/drug therapy; Programmed Cell Death 1 Receptor/antagonists & inhibitors; Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological/administration & dosage; Clinical Trials as Topic; Cytokines/therapeutic use; Disease Progression; Humans; Immunotherapy, Adoptive/methods; Ipilimumab; Lymphocytes, Tumor-Infiltrating/metabolism; Melanoma/pathology; Melanoma/therapy; Mitogen-Activated Protein Kinases/antagonists & inhibitors; Neoplasm Metastasis; OX40 Ligand/immunology; Oncolytic Virotherapy/methods; Proto-Oncogene Proteins B-raf; Radiotherapy, Adjuvant/methods; Receptors, Chimeric Antigen/drug effects; Toll-Like Receptors/agonists; Tumor Microenvironment/immunology; Tumor Necrosis Factor Receptor Superfamily, Member 9/immunology

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: CTLA-4 Antigen / Programmed Cell Death 1 Receptor / Antineoplastic Agents, Immunological / Melanoma Limits: Humans Language: En Journal: Oncology (Williston Park) Journal subject: NEOPLASIAS Year: 2019 Type: Article

Search on Google

XML

PubMed Links